The design and unbiased nature of Cognition Therapeutics’ primary screening platform suits it well to repurposing for drug discovery in other neurodegenerative diseases where toxic soluble oligomeric proteins are implicated. Cognition Therapeutics has recently had success in developing a platform to measure alpha-synuclein oligomer pathophysiology and is currently using this to screen several chemical libraries for novel compounds with therapeutic potential in Parkinson’s disease.